LIQUID BIOPSY AS A DIAGNOSTIC TOOL FOR EARLY CANCER DETECTION
DOI:
https://doi.org/10.25215/0557983827.13Abstract
Liquid biopsy has emerged as a minimally invasive diagnostic strategy for the early detection of malignant disease, relying on the analysis of tumor-derived material circulating in blood and other body fluids. This chapter reviews the biological rationale, principal analyte classes, and detection platforms underlying liquid biopsy, including cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and non-coding RNAs. Particular attention is given to multi-cancer early detection (MCED) technologies and the clinical evidence generated by large prospective trials, which together illustrate both the promise and the present limitations of blood-based screening. The persistent trade-off between sensitivity in early-stage disease and population-level specificity is examined alongside biological confounders such as clonal haematopoiesis. The chapter concludes by considering the practical responsibilities of allied health professionals in specimen handling, patient counselling, and result communication, and by outlining the regulatory, technical, and equity barriers that must be addressed before liquid biopsy can be integrated into routine cancer-screening pathways.Published
2026-07-03
Issue
Section
Articles
